Skip to main content
Rapid Reactions

Zongertinib, a Novel HER2-Specific Tyrosine Kinase Inhibitor for HER2-Positive Solid Tumors with Brain Metastases

Rapid Reactions
WCLC 2024 HER2-Mutated NSCLC
Videos

In this video, Beth Sandy, MSN, CRNP, FAPO, discusses data showing that zongertinib demonstrated manageable safety and promising efficacy in patients with HER2 aberration-positive solid tumors, including those with baseline brain metastases.

Portrait of Beth Sandy, MSN, CRNP, FAPO

Beth Sandy, MSN, CRNP, FAPO
Thoracic Oncology Nurse Practitioner
Abramson Cancer Center, University of Pennsylvania
Philadelphia, PA

Sponsored by

Boehringer Ingelheim Logo

Related Items

Longer-Term Follow-Up of Amivantamab + Lazertinib vs Osimertinib From the MARIPOSA Study
Videos
Rapid Reactions
HARMONi-2: Phase 3 Study of Ivonescimab vs Pembrolizumab in 1L Treatment for Patients with PD-L1-Positive Advanced NSCLC
Videos
Rapid Reactions
Targeting HER2-Mutated NSCLC With Zongertinib
Videos
Rapid Reactions
Updated Data From ASCO of Beamion LUNG-1, a Phase 1a/1b Trial of Zongertinib in Patients With HER2 Aberration-Positive Solid Tumors
Videos
Rapid Reactions